FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1592393060> ?p ?o ?g. }

• W1592393060 endingPage "135" @default.
• W1592393060 startingPage "126" @default.
• W1592393060 abstract "Costimulation blockade of the CD40/CD154 pathway has been effective at preventing allograft rejection in numerous transplantation models. This strategy has largely depended on mAbs directed against CD154, limiting the potential for translation due to its association with thromboembolic events. Though targeting CD40 as an alternative to CD154 has been successful at preventing allograft rejection in preclinical models, there have been no reports on the effects of CD40-specific agents in human transplant recipients. This delay in clinical translation may in part be explained by the presence of cellular depletion with many CD40-specific mAbs. As such, the optimal biologic properties of CD40-directed immunotherapy remain to be determined. In this report, we have characterized 3A8, a human CD40-specific mAb and evaluated its efficacy in a rhesus macaque model of islet cell transplantation. Despite partially agonistic properties and the inability to block CD40 binding of soluble CD154 (sCD154) in vitro, 3A8-based therapy markedly prolonged islet allograft survival without depleting B cells. Our results indicate that the allograft-protective effects of CD40-directed costimulation blockade do not require sCD154 blockade, complete antagonism or cellular depletion, and serve to support and guide the continued development of CD40-specific agents for clinical translation. Costimulation blockade of the CD40/CD154 pathway has been effective at preventing allograft rejection in numerous transplantation models. This strategy has largely depended on mAbs directed against CD154, limiting the potential for translation due to its association with thromboembolic events. Though targeting CD40 as an alternative to CD154 has been successful at preventing allograft rejection in preclinical models, there have been no reports on the effects of CD40-specific agents in human transplant recipients. This delay in clinical translation may in part be explained by the presence of cellular depletion with many CD40-specific mAbs. As such, the optimal biologic properties of CD40-directed immunotherapy remain to be determined. In this report, we have characterized 3A8, a human CD40-specific mAb and evaluated its efficacy in a rhesus macaque model of islet cell transplantation. Despite partially agonistic properties and the inability to block CD40 binding of soluble CD154 (sCD154) in vitro, 3A8-based therapy markedly prolonged islet allograft survival without depleting B cells. Our results indicate that the allograft-protective effects of CD40-directed costimulation blockade do not require sCD154 blockade, complete antagonism or cellular depletion, and serve to support and guide the continued development of CD40-specific agents for clinical translation." @default.
• W1592393060 created "2016-06-24" @default.
• W1592393060 creator A5000972680 @default.
• W1592393060 creator A5003099842 @default.
• W1592393060 creator A5036799246 @default.
• W1592393060 creator A5036996080 @default.
• W1592393060 creator A5039861729 @default.
• W1592393060 creator A5046944474 @default.
• W1592393060 creator A5056227972 @default.
• W1592393060 creator A5056389032 @default.
• W1592393060 creator A5062306820 @default.
• W1592393060 creator A5065097406 @default.
• W1592393060 creator A5083086278 @default.
• W1592393060 creator A5084074784 @default.
• W1592393060 creator A5087476769 @default.
• W1592393060 creator A5090680688 @default.
• W1592393060 date "2012-01-01" @default.
• W1592393060 modified "2023-10-17" @default.
• W1592393060 title "Nondepleting Anti-CD40-Based Therapy Prolongs Allograft Survival in Nonhuman Primates" @default.
• W1592393060 cites W1485526722 @default.
• W1592393060 cites W1523655008 @default.
• W1592393060 cites W1528086703 @default.
• W1592393060 cites W154131955 @default.
• W1592393060 cites W1561516029 @default.
• W1592393060 cites W1581554632 @default.
• W1592393060 cites W1593640213 @default.
• W1592393060 cites W1606436237 @default.
• W1592393060 cites W1623137528 @default.
• W1592393060 cites W1669283189 @default.
• W1592393060 cites W1674225733 @default.
• W1592393060 cites W1976046966 @default.
• W1592393060 cites W1979721491 @default.
• W1592393060 cites W1992857382 @default.
• W1592393060 cites W1998555578 @default.
• W1592393060 cites W2002905931 @default.
• W1592393060 cites W2017390384 @default.
• W1592393060 cites W2025631961 @default.
• W1592393060 cites W2025757893 @default.
• W1592393060 cites W2043419802 @default.
• W1592393060 cites W2054083392 @default.
• W1592393060 cites W2054540030 @default.
• W1592393060 cites W2058942284 @default.
• W1592393060 cites W2059791530 @default.
• W1592393060 cites W2067152527 @default.
• W1592393060 cites W2068225706 @default.
• W1592393060 cites W2070288789 @default.
• W1592393060 cites W2086267154 @default.
• W1592393060 cites W2112036459 @default.
• W1592393060 cites W2121500468 @default.
• W1592393060 cites W2137099568 @default.
• W1592393060 cites W2171678230 @default.
• W1592393060 doi "https://doi.org/10.1111/j.1600-6143.2011.03736.x" @default.
• W1592393060 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3259281" @default.
• W1592393060 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21920020" @default.
• W1592393060 hasPublicationYear "2012" @default.
• W1592393060 type Work @default.
• W1592393060 sameAs 1592393060 @default.
• W1592393060 citedByCount "67" @default.
• W1592393060 countsByYear W15923930602012 @default.
• W1592393060 countsByYear W15923930602013 @default.
• W1592393060 countsByYear W15923930602014 @default.
• W1592393060 countsByYear W15923930602015 @default.
• W1592393060 countsByYear W15923930602016 @default.
• W1592393060 countsByYear W15923930602017 @default.
• W1592393060 countsByYear W15923930602018 @default.
• W1592393060 countsByYear W15923930602019 @default.
• W1592393060 countsByYear W15923930602020 @default.
• W1592393060 countsByYear W15923930602022 @default.
• W1592393060 countsByYear W15923930602023 @default.
• W1592393060 crossrefType "journal-article" @default.
• W1592393060 hasAuthorship W1592393060A5000972680 @default.
• W1592393060 hasAuthorship W1592393060A5003099842 @default.
• W1592393060 hasAuthorship W1592393060A5036799246 @default.
• W1592393060 hasAuthorship W1592393060A5036996080 @default.
• W1592393060 hasAuthorship W1592393060A5039861729 @default.
• W1592393060 hasAuthorship W1592393060A5046944474 @default.
• W1592393060 hasAuthorship W1592393060A5056227972 @default.
• W1592393060 hasAuthorship W1592393060A5056389032 @default.
• W1592393060 hasAuthorship W1592393060A5062306820 @default.
• W1592393060 hasAuthorship W1592393060A5065097406 @default.
• W1592393060 hasAuthorship W1592393060A5083086278 @default.
• W1592393060 hasAuthorship W1592393060A5084074784 @default.
• W1592393060 hasAuthorship W1592393060A5087476769 @default.
• W1592393060 hasAuthorship W1592393060A5090680688 @default.
• W1592393060 hasBestOaLocation W15923930601 @default.
• W1592393060 hasConcept C126322002 @default.
• W1592393060 hasConcept C154317977 @default.
• W1592393060 hasConcept C170493617 @default.
• W1592393060 hasConcept C202751555 @default.
• W1592393060 hasConcept C203014093 @default.
• W1592393060 hasConcept C2777701055 @default.
• W1592393060 hasConcept C2778468042 @default.
• W1592393060 hasConcept C2779234475 @default.
• W1592393060 hasConcept C2911091166 @default.
• W1592393060 hasConcept C39347974 @default.
• W1592393060 hasConcept C55493867 @default.
• W1592393060 hasConcept C71924100 @default.
• W1592393060 hasConcept C86803240 @default.

• next